New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Eupraxia Pharmaceuticals Inc.

Contributing Author

Recent Articles by Eupraxia Pharmaceuticals Inc.

Sep-29	Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs EPRX GlobeNewswire
Sep-24	Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option EPRX GlobeNewswire
Sep-22	Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares EPRX GlobeNewswire
Sep-22	Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares EPRX GlobeNewswire
Sep-02	First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI EPRX GlobeNewswire
Aug-12	Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update EPRX GlobeNewswire
Jul-22	Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences EPRX GlobeNewswire
Jul-08	Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis EPRX GlobeNewswire
Jun-02	Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders EPRX GlobeNewswire
May-07	Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 EPRX GlobeNewswire
May-06	Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results EPRX GlobeNewswire
May-05	Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI EPRX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.